#1 Clinical Trials Search in Europe

Pegargiminase

Pegargiminase, also known as ADI-PEG 20, is an innovative drug being studied in clinical trials for the treatment of various types of cancer, including small cell lung cancer and soft tissue sarcomas. This article explores the use of Pegargiminase in clinical trials, its potential benefits, and what patients should know about this experimental treatment.

Table of Contents

What is PEGARGIMINASE?

PEGARGIMINASE, also known as ADI-PEG 20 or pegylated arginine deiminase, is a promising drug being studied for the treatment of various types of cancer[1][2]. It is a specially designed enzyme that has been modified to work more effectively in the human body.

The drug is created by taking an enzyme called arginine deiminase (ADI) from a type of bacteria and attaching it to a substance called polyethylene glycol (PEG)[2]. This process, known as pegylation, helps the drug last longer in the body and reduces the chances of the immune system attacking it.

How Does PEGARGIMINASE Work?

PEGARGIMINASE works by breaking down an amino acid called arginine in the blood[1]. Many cancer cells rely heavily on arginine to grow and survive. By depleting arginine levels in the blood, PEGARGIMINASE can potentially slow down or stop the growth of these cancer cells.

Interestingly, some cancer cells lack an enzyme called argininosuccinate synthase 1 (ASS1), which is needed to produce arginine[2]. These ASS1-deficient cancer cells are particularly vulnerable to PEGARGIMINASE treatment because they can’t make their own arginine and must rely on arginine from the blood.

Conditions Treated with PEGARGIMINASE

PEGARGIMINASE is being studied for the treatment of several types of cancer, including:

  • Small Cell Lung Cancer (SCLC): A fast-growing type of lung cancer[1]
  • Soft Tissue Sarcoma: Cancer that develops in soft tissues like muscles, fat, or blood vessels[2]
  • Osteosarcoma: A type of bone cancer[2]
  • Ewing’s Sarcoma: Another type of cancer that affects bones and soft tissues[2]

Clinical Trials Involving PEGARGIMINASE

Several clinical trials have been conducted to study the effectiveness and safety of PEGARGIMINASE:

1. A Phase II study for Small Cell Lung Cancer: This trial tested PEGARGIMINASE in patients with SCLC who had already received previous treatment[1]. The study looked at how well the drug worked on its own for this type of cancer.

2. A Phase II trial combining PEGARGIMINASE with other chemotherapy drugs: This ongoing study is testing PEGARGIMINASE in combination with two other cancer drugs, gemcitabine and docetaxel, for the treatment of various types of sarcomas and small cell lung cancer[2]. The researchers believe that PEGARGIMINASE might make the cancer cells more sensitive to the effects of the other drugs.

How is PEGARGIMINASE Administered?

PEGARGIMINASE is typically given as an intramuscular (IM) injection, which means it’s injected directly into a muscle. In clinical trials, it has been administered in the following ways:

  • A fixed dose of 320 IU/m² (which is equivalent to 36.8 mg/m²) once weekly[1]
  • Injections are usually given in the arm (deltoid muscle) or buttock (gluteal muscle)[2]
  • Treatment is often given in cycles, with each cycle lasting several weeks[1][2]

Potential Side Effects

As with all medications, PEGARGIMINASE may cause side effects. In clinical trials, researchers carefully monitor patients for any adverse events (unwanted effects). These can range from mild to severe. Common side effects may include injection site reactions, fatigue, or changes in blood tests. However, it’s important to note that the full range of potential side effects is still being studied[1][2].

Future Research and Potential

PEGARGIMINASE is still considered an experimental drug, which means it’s not yet approved for general use outside of clinical trials. Researchers are continuing to study its effectiveness and safety, both alone and in combination with other cancer treatments[2].

One exciting area of research is how PEGARGIMINASE might make cancer cells more vulnerable to other treatments. For example, studies have shown that depleting arginine can cause cancer cells to change how they use energy, potentially making them more sensitive to certain chemotherapy drugs[2].

As research continues, we may learn more about which patients are most likely to benefit from PEGARGIMINASE and how best to use it in cancer treatment. While the results so far are promising, more studies are needed before this drug could become widely available for cancer patients.

Aspect Details
Drug Name Pegargiminase (ADI-PEG 20)
Mechanism Arginine-depleting enzyme
Administration Intramuscular injection, typically weekly
Dosage Usually 320 IU/m² or 36 mg/m²
Cancer Types Studied Small cell lung cancer, soft tissue sarcoma, osteosarcoma, Ewing’s sarcoma
Trial Combinations Alone or with gemcitabine and docetaxel
Primary Outcomes Tumor response, progression-free survival
Secondary Outcomes Overall survival, clinical benefit rate, safety and tolerability
Treatment Duration Varies by trial, up to 34 cycles (about 2 years)
Current Status In Phase II clinical trials

FAQ

  • What is Pegargiminase (ADI-PEG 20)? Pegargiminase, or ADI-PEG 20, is a modified enzyme that depletes arginine in the body. It's made from a protein found in bacteria and is attached to a substance called PEG to help it work better in the body. This drug is being studied as a potential treatment for certain types of cancer.
  • What types of cancer is Pegargiminase being tested for? Pegargiminase is being tested in clinical trials for several types of cancer, including small cell lung cancer, soft tissue sarcoma, osteosarcoma, and Ewing's sarcoma. These trials are exploring its effectiveness both alone and in combination with other cancer drugs.
  • How is Pegargiminase administered in clinical trials? In the clinical trials, Pegargiminase is typically given as an intramuscular injection (a shot into the muscle) once a week. The dose is usually based on the patient's body surface area, with a common dose being 320 IU/m² or 36 mg/m².
  • What are the potential side effects of Pegargiminase? As with any drug in clinical trials, the full range of side effects is still being studied. However, common side effects of cancer treatments can include fatigue, nausea, and changes in blood cell counts. The trials are closely monitoring patients for any adverse events to ensure safety.
  • How long do patients receive Pegargiminase in these trials? The duration of treatment varies depending on the specific trial and the patient's response to the drug. In some trials, treatment cycles last 4 weeks, while in others, patients may receive treatment for up to 34 cycles (about 2 years) if they continue to benefit from the drug and don't experience severe side effects.

Ongoing Clinical Trials on Pegargiminase

  • Study of Troriluzole and ADI-PEG-20 for Patients with Newly Diagnosed and Recurrent Glioblastoma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany

Glossary

  • Pegargiminase (ADI-PEG 20): A modified enzyme drug that depletes arginine in the body, being studied for cancer treatment. It's made from a bacterial protein and attached to polyethylene glycol (PEG) to improve its effectiveness.
  • Arginine: An amino acid that some cancer cells need to grow. Pegargiminase works by reducing the amount of arginine available to cancer cells.
  • Intramuscular injection: A method of giving medicine by injecting it directly into a muscle, often in the arm or buttock.
  • Clinical trial: A research study that tests how well new medical approaches work in people, such as new ways to prevent, detect, or treat diseases like cancer.
  • Small cell lung cancer (SCLC): A fast-growing type of lung cancer that usually starts in the bronchi (center of the chest).
  • Soft tissue sarcoma: A type of cancer that starts in soft tissues of the body, such as muscles, tendons, fat, lymph vessels, blood vessels, and nerves.
  • Osteosarcoma: The most common type of bone cancer, usually developing in the bones of the arms, legs, or pelvis.
  • Ewing's sarcoma: A rare type of cancer that occurs in bones or in the soft tissue around the bones, often affecting children and young adults.
  • Gemcitabine: A chemotherapy drug used to treat various types of cancer, including lung cancer and soft tissue sarcoma.
  • Docetaxel: A chemotherapy drug belonging to the taxane family, used to treat several types of cancer.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall survival (OS): The length of time from the start of treatment for a disease that patients are still alive.
  • Clinical benefit rate (CBR): The percentage of patients whose cancer shrinks or remains stable for a minimum period of time after treatment.
  • Adverse event: Any unfavorable and unintended sign, symptom, or disease associated with the use of a medical treatment or procedure.

References

  1. https://clinicaltrials.gov/study/NCT01266018
  2. https://clinicaltrials.gov/study/NCT03449901